AstraZeneca plc (NYSE: AZN) is one of 116 publicly-traded companies in the “Pharmaceuticals” industry, but how does it contrast to its rivals? We will compare AstraZeneca plc to similar companies based on the strength of its valuation, profitability, institutional ownership, analyst recommendations, earnings, risk and dividends.
Institutional and Insider Ownership
14.2% of AstraZeneca plc shares are owned by institutional investors. Comparatively, 42.4% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 11.7% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
This table compares AstraZeneca plc and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AstraZeneca plc Competitors||-2,925.59%||-70.76%||-9.78%|
This is a summary of recent ratings and recommmendations for AstraZeneca plc and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AstraZeneca plc Competitors||846||3755||6778||185||2.54|
AstraZeneca plc presently has a consensus target price of $37.40, indicating a potential upside of 8.45%. As a group, “Pharmaceuticals” companies have a potential upside of 33.55%. Given AstraZeneca plc’s rivals stronger consensus rating and higher possible upside, analysts clearly believe AstraZeneca plc has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares AstraZeneca plc and its rivals revenue, earnings per share and valuation.
|Gross Revenue||NetIncome||Price/Earnings Ratio|
|AstraZeneca plc||$23.00 billion||$3.50 billion||11.30|
|AstraZeneca plc Competitors||$8.39 billion||$1.12 billion||134.48|
AstraZeneca plc has higher revenue and earnings than its rivals. AstraZeneca plc is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
AstraZeneca plc has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, AstraZeneca plc’s rivals have a beta of 32.56, meaning that their average stock price is 3,156% more volatile than the S&P 500.
AstraZeneca plc pays an annual dividend of $1.37 per share and has a dividend yield of 4.0%. AstraZeneca plc pays out 44.9% of its earnings in the form of a dividend. As a group, “Pharmaceuticals” companies pay a dividend yield of 2.5% and pay out 65.5% of their earnings in the form of a dividend. AstraZeneca plc is clearly a better dividend stock than its rivals, given its higher yield and lower payout ratio.
AstraZeneca plc rivals beat AstraZeneca plc on 8 of the 15 factors compared.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.